Martin Bonde
EpiTherapeutics is developing novel innovative cancer drugs based on the world leading research in epigenetics conducted by Professor Kristian Helin and his group at Biotech Research & Innovation Centre (BRIC) at University of Copenhagen.
EpiTherapeutics' development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. Subsequent developments may identify other potential clinical indications outside oncology.
In December 2010, Epitherapeutics signed a drug discovery collaboration with Abbott Laboratories.
Epitherapeutics employs 25 FTE and is headquartered in Copenhagen.
